Announcement of TTY Biopharm's unaudited income information in April 2024

2024.5.13

Provided by: TTY BIOPHARM COMPANY LIMITED
SEQ_NO 1 Date of announcement 2024/05/13 Time of announcement 16:25:13
Subject Announcement of TTY Biopharm's unaudited income information in April 2024
Date of events 2024/05/13 To which item it meets paragraph 53
Statement 1.Date of occurrence of the event:2024/05/13
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $456,707 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $42,990 thousands, and a consolidated income before tax of $67,159 thousands in April 2024; net income attributed to stockholders of the company was $47,799 thousands; EPS is $0.19.
Year-to-date consolidated net sales was $1,730,312 thousands (in NTdollars; unaudited), a consolidated operating profit was $352,892 thousands, and consolidated income before tax was $435,215 thousands until April 2024; year-to-date net income attributed to stockholders of the company was $328,571 thousands; EPS is $1.32.
6.Countermeasures:None.
7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail.
TOP